Paul Colvin has been appointed president, Clinical Solutions, Syneos Health. Mr. Colvin joins the company from Pharmaceutical Product Development, LLC (PPD), where he served as executive vice president, Biopharma Partnerships and chairman and chief executive officer of PPD-SNBL, a joint venture that has grown to be one of the largest clinical development service providers in Japan. He succeeds Michael McKelvey, PhD., who has announced his retirement.

Prior to PPD, Mr. Colvin spent nearly 15 years at Eli Lilly and Company in a variety of increasingly significant roles gaining global, operational and patient enrollment experience across multiple therapeutic areas. While there he served as head of Clinical Operations and Global Patient Enrollment Optimization, Chief Operations Officer of the Cardiovascular Global Brand team, Head of European Clinical Operations and Head of Global Clinical Operations for the Oncology Product team.

“We’re thrilled to welcome Paul to lead Syneos Health’s global clinical research organization,” said Alistair Macdonald, Chief Executive Officer, Syneos Health. “Paul’s significant experience in global clinical development adds immediate and further know-how to our Clinical offering. His deep CRO expertise, coupled with an ability to sync solutions with our Commercial offerings, is a natural fit for our biopharmaceutical acceleration model.”